Biotech

Latest Articles

Basilea ratings $268M BARDA financing for antifungals, prescription antibiotics

.Basilea Pharmaceutica's job developing brand-new antifungals has actually obtained a substantial bo...

Capricor markets Europe civil liberties to late-stage DMD treatment for $35M

.Having already scooped up the USA civil liberties to Capricor Therapeutics' late-stage Duchenne mus...

FDA fragments adcomm for Applied's uncommon illness medicine

.After pushing back the choice meeting for Applied Therapeutics' metabolic problem medication govore...

Novo inks $600M NanoVation package to study hereditary medications ex-liver

.Novo Nordisk is actually proceeding its own push right into hereditary medicines, accepting to comp...

Innovent hyperlinks cytokine to colorectal cancer actions

.Innovent Biologics has actually made the case that its gate inhibitor-cytokine fusion protein has a...

Merck, Daiichi ADC attacks goal in period 3 lung cancer cells research

.A stage 3 test of Daiichi Sankyo and also Merck &amp Co.'s HER3-directed antibody-drug conjugate (A...

Rakovina grows AI concentrate along with collab to decide on cancer cells targets

.Five months after Rakovina Rehabs rotated toward artificial intelligence, the cancer-focused biotec...

Ascendis' dwarfism medicine smash hits in stage 3, threatens BioMarin

.Ascendis Pharma has actually become a potential risk to BioMarin's Voxzogo, stating phase 3 growth ...

Despite ph. 3 overlook, Alkeus finds road in advance for eye illness asset

.Though Alkeus Pharmaceuticals' dental eye ailment property neglected to substantially decrease geog...

Kairos goes public along with $6M IPO to fund tests of cancer medicine

.Along with a triad of biotechs hitting the Nasdaq on Friday, it was actually quick and easy to over...

Vaccine and Keytruda combination effective in squamous cell carcinoma

.Invulnerable gate preventions are the superheroes of cancer cells treatment. Drugs like Bristol Mye...

Cue Biopharma mark time J&ampJ vet as CBO-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our roundup of notable leadership hirings, shootings as...

Regeneron's Opdualag competitor shows 57% response price

.Regeneron is back along with long-term follow-up for its LAG-3 inhibitor and also PD-1 inhibitor co...

AstraZeneca blog posts records on in-house opponents to AbbVie, Pfizer ADCs

.AstraZeneca has actually discussed an early consider the performance of its own in-house antibody-d...

iTeos- GSK's TIGIT celebrity reveals meaningful improvement

.After revealing a period 3 launch based upon positive midstage end results, iTeos as well as GSK ar...

More joint FDA may increase rare disease R&ampD: report

.The FDA needs to be a lot more open and also collective to let loose a surge in commendations of un...

Zenas, MBX, Bicara scalp to Nasdaq in very hot time for biotech IPOs

.It is actually an abnormally occupied Friday for biotech IPOs, with Zenas BioPharma, MBX as well as...

Atea's COVID antiviral falls short to stop hospitalizations in stage 3

.Atea Pharmaceuticals' antiviral has stopped working one more COVID-19 trial, however the biotech st...

Neurocrine's bid to spare mental illness prospect stops working

.Neurocrine Biosciences' mental illness system pivot has stopped working. The biotech was actually u...

Sanofi pays out $110M upfront for late-stage radioligand treatment

.Sanofi has created a late access to the radioligand party, spending one hundred thousand europeans ...